GlassScriptPhysician profile
Grigor Grigoryan
NPI 1205382231
$6,239.12
in general payments reported to CMS, 2019-2025
29 companies · $559 in 2025
The $559 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,713 · 2022: $1,534 · 2023: $1,165 · 2024: $1,268 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,980 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,980.25 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,105.92 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $933.17 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $869.73 | 2021-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $865.34 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $485.37 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $303.91 | 2021-2023 | Trintellix |
| Alkermes, INC. | $246.57 | 2021-2022 | |
| Tris Pharma INC | $225.08 | 2022-2024 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $175.60 | 2021 | |
| Corium, LLC | $159.13 | 2021-2024 | Azstarys |
| Neuronetics, INC. | $148.05 | 2022-2025 | Neurostar Tms Therapy System |
| Bausch Health US, LLC | $92.95 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $77.69 | 2021-2025 | Keytruda, Welireg |
| Stemline Therapeutics INC. | $65.18 | 2025 | Orserdu |
| Lundbeck LLC | $57.23 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $54.00 | 2021-2025 | |
| Alfasigma USA, INC. | $53.02 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $52.83 | 2024-2025 | Cobenfy |
| Indivior INC. | $48.64 | 2021-2024 | Sublocade |
| Axsome Therapeutics, INC. | $45.80 | 2023 | Sunosi, Auvelity |
| Recordati_rare_diseases_inc. | $28.35 | 2025 | Sylvant |
| Pharmaand Gmbh | $28.00 | 2025 | Rubraca |
| Almatica Pharma LLC | $23.24 | 2021 | |
| Aytu Biopharma, INC. | $17.56 | 2021 | |
| Noven Therapeutics, LLC | $17.50 | 2023 | Secuado |
| Owp Pharmaceuticals, INC. | $16.59 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.98 | 2024 | Quviviq |
| Neurocrine Biosciences, INC. | $14.02 | 2024 | Ingrezza |
| Medtronic, INC. | $13.67 | 2024 | Plasmablade(Tm) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grigor Grigoryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.